FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 2143-2146

  Lu, Chien Yu ^a,b   Yeh, Yung Sung ^b,c,d   Huang, Ching Wen ^b,d   Ma, Cheng Jen ^b,d   Yu, Fang Jung ^a,b   Wang, Jaw Yuan ^b,d,e,f  

^a Division of Gastroenterology   (Taiwan)

^b School of Chinese Medicine   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Dose escalation; Irinotecan; Metastatic colon cancer; Regorafenib; UGT1A1

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; OXALIPLATIN; REGORAFENIB;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; COLON ADENOCARCINOMA; COLON BIOPSY; COLON CANCER; COLON CARCINOMA; COLON TUMOR; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DESCENDING COLON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; GENOTYPE; HAND FOOT SYNDROME; HISTOLOGY; HUMAN; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; REPEATED DRUG DOSE; TREATMENT DURATION; UGT1A1 GENE;

EID: 84912108044     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S69774     Document Type: Article

References (17)

1. Arnold D, Stein A. New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy. Drugs. 2013;73(9):883–891.
2. Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol. 2010;21 Suppl 5:v93–v97.
3. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26(35): 5721–5727.
4. Ocvirk J, Brodowicz T, Wrba F, et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol. 2010;16(25):3133–3143.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342.
6. Yeh YS, Huang ML, Chang SF, Chen CF, Hu HM, Wang JY. FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 Genotyping. Med Princ Pract. 2014;23(5):478–481.
7. Lu CY, Huang CW, Hu HM, et al. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting. Transl Res. 2014;164(2):169–176.
8. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7(8): 2182–2194.
9. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998;101(4):847–854.
10. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert’s syndrome. Lancet. 1996;347(9001):578–581.
11. Marcuello E, Paez D, Pare L, et al. A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer. 2011;105(1):53–57.
12. Hebbar M, Ychou M, Ducreux M. Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2009;135(6):749–752.
13. Tsai H-L, Chen C-F, Lu C-Y, et al. Significant correlation between polymorphisms of UGT1A1 gene and low irinotecan toxicity in colorectal cancer patients with FOLFIRI. Open Colorectal Cancer Journal. 2009;2:21–26.
14. Crona DJ, Keisler MD, Walko CM. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors. Ann Pharmacother. 2013;47(12):1685–1696.
15. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.
16. De Wit M, Boers-Doets CB, Saettini A, et al. Prevention and management of adverse events related to regorafenib. Support Care Cancer. 2014;22(3):837–846.
17. Schultheis B, Folprecht G, Kuhlmann J, et al. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol. 2013;24(6):1560–1567.